指南与共识类风湿关节炎脊柱关节炎系统性红斑狼疮

风湿病患者妊娠与生殖健康中改善病情抗风湿药使用推荐:范围综述

Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2025-06-16

该范围综述检索Medline和Embase并手工检索,纳入2014年以来风湿病学术机构发布的18部指南,比较妊娠与生殖健康中改善病情抗风湿药(DMARDs)使用推荐。孕前推荐见于10部指南(56%),哺乳期12部(67%),男性生育6部(33%)。传统合成DMARDs推荐相对一致且证据中等,生物制剂和靶向合成DMARDs推荐差异大、证据极少。

要点

  • 18部指南中,孕前DMARDs推荐见于10部(56%),哺乳期12部(67%),男性生育仅6部(33%)。
  • 13部指南(72%)含传统合成DMARDs推荐,13部(72%)含生物制剂推荐,5部(28%)含靶向合成DMARDs推荐。
  • 传统合成DMARDs推荐相对一致且证据中等,生物制剂和靶向合成DMARDs推荐差异大、证据极少。

核心结论

  • 妊娠期DMARDs使用指南的制定存在异质性。
  • 传统合成DMARDs推荐在各指南间相似。
  • 生物制剂和靶向合成DMARDs推荐差异显著,反映该领域现有文献极少。

研究设计与样本

  • 范围综述,检索Medline和Embase并辅以手工检索。
  • 纳入2014年以来风湿病学术机构发布的、涉及类风湿关节炎、强直性脊柱炎、银屑病关节炎或系统性红斑狼疮妊娠期DMARDs管理的指南。
  • 共纳入18部指南,由两名作者(AC、AT)重复进行数据提取。

主要发现

  • 孕前DMARDs使用推荐见于10部指南(56%),哺乳期见于12部指南(67%),男性生育见于6部指南(33%)。
  • 13部指南(72%)含传统合成DMARDs推荐,13部指南(72%)含生物制剂推荐,5部指南(28%)含靶向合成DMARDs推荐。
  • 与传统合成DMARDs推荐相对一致且证据中等相比,生物制剂和靶向合成DMARDs推荐证据极少且各异。

关键数值与推荐

  • 传统合成DMARDs包括甲氨蝶呤、柳氮磺吡啶、来氟米特和羟氯喹。
  • 生物制剂DMARDs包括阿达木单抗、依那西普、英夫利西单抗、戈利木单抗、培塞利珠单抗、阿巴西普、托珠单抗、利妥昔单抗和阿那白滞素。
  • 靶向合成DMARDs包括托法替布、巴瑞替尼和乌帕替尼。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 妊娠期DMARDs使用指南的制定存在异质性。
  • 生物制剂和靶向合成DMARDs推荐差异显著,反映该领域现有文献极少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease-modifying antirheumatic drugs (DMARDs) has fostered more suitable conditions for pregnancy; however, this is accompanied by challenges in ensuring safe use in reproductive health. The aim of this review is to compare existing guideline recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease. METHODS: A scoping review was performed with Medline and Embase, in addition to a hand search, to identify guidelines published since 2014 by academic societies in rheumatology that addressed the management of DMARDs in pregnancy in any of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus. Conventional synthetic DMARDs (csDMARDs) (methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine), biologic DMARDs (bDMARDs) (adalimumab, etanercept, infliximab, golimumab, certolizumab, abatacept, tocilizumab, rituximab, and anakinra), and targeted synthetic DMARDs (tsDMARDs) (tofacitinib, baricitinib, and upadacitinib) were targeted. Two authors performed data extraction in duplicate (AC, AT). RESULTS: A total of 18 guidelines were included. Recommendations for DMARD use in preconception were present in 10 guidelines (56%), lactation in 12 guidelines (67%), and male fertility in 6 guidelines (33%). A total of 13 guidelines (72%) included recommendations for csDMARDs, 13 guidelines (72%) included recommendations for bDMARDs, and 5 guidelines (28%) included recommendations for tsDMARDs. There was moderate evidence supporting relatively uniform csDMARD recommendations, compared to minimal evidence for bDMARD and tsDMARD use with variable recommendations. CONCLUSION: There is heterogeneity in the formulation of guidelines on the use of DMARDs in pregnancy. Recommendations for csDMARDs were similar between guidelines. There was significant variability in recommendations for bDMARD and tsDMARD use, reflecting current minimal literature in this area.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Chin A, Terrett A, Kwon M, et al. Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review. Arthritis Care Res (Hoboken). 2025. PMID: 40256995. doi:10.1002/acr.25558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。